The clinical implications of inhibition of the inducible form of cyclo-oxygenase

Drug Safety

Volumn 15, Issue 4, 1996, Pages 249-260

  Richardson, Charles ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; ACETYLSALICYLIC ACID; AZAPROPAZONE; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; TENOXICAM;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BRAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DYSPEPSIA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOSTASIS; HUMAN; KIDNEY FUNCTION; NAUSEA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RASH; REVIEW; SEMINAL VESICLE; SKELETAL MUSCLE; STOMACH MUCOSA; STOMACH ULCER; TISSUE DISTRIBUTION; UTERUS FUNCTION; VERTIGO;

EID: 0029909989     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615040-00003     Document Type: Review

References (61)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin like drugs. Nature 1971; 231: 235-7
2. Smith WL, Borgeat P, Fitzpatrick FA. The eicosanoids: cyclooxygenase, lipooxygenase, and epoxygenase pathways. In: Vance De, Vance J, editors. Biochemistry of lipids, lipoproteins and membranes. Oxford: Elsevier Science Publishers. 1991: 297-325
3. Solomon LM, Juhlin L, Kirchenbain MB. Prostaglandins on cutaneous vasculature. J Invest Dermatol 1968; 51: 280-2
4. Ferreira SH. Prostaglandins, aspirin like drugs and analgesia. Nature 1992; 240: 200-3
5. Appleton I, Tomlinson A, Mitchell JA, et al. Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. J Pathol 1995; 176 (4): 413-20
6. Dunn MJ. Non steroidal anti inflammatory drugs and renal function. Annu Rev Med 1984; 35: 411-28
7. Miller TA. Protective effects of prostaglandins against mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601-23
8. Bunting S, Moncada S, Vane JR. The prostacyclin-thromboxane balance: pathophysiological and therapeutic considerations. Br Med Bull 1983; 39: 271-6
9. O'Banion MK, Sadowski HB, Winn V, et al. A serum and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase related protein. J Biol Chem 1991; 266: 23261-7
10. Kujubu DA, Herschman HR. Dexamethasone inhibits nitrogen induction of the TIS10 prostaglandin synthase/cyclo-oxygenase gene. J Biol Chem 1992; 267: 7991-4
11. Sirois J, Richards JS. Purification and characterisation of a novel, distinct isoform of prostaglandin enderoperoxide synthase induced by human chorionic gonadotrophin in granulosa cells of rat pre ovulatory follicles. J Biol Chem 1992; 267: 6382-8
12. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclooxygenase (COX2): a safer therapeutic target? Br J Rheumatol 1995; 33 (5): 410-2
13. Mead EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non steroidal anti inflammatory drugs. J Biol Chem 1992; 268: 6610-4
14. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6
15. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase 1 and 2 expression in rheumatoid synovial tissues: effect of interleukin 1β, Phorbol esters, and corticosteroids. J Clin Invest 1994; 93: 1095-101
16. Knott I, Dieu M, Burton M, et al. Induction of cyclooxygenase by interleukin 1: comparative study between human synovial cells and chondrocytes. J Rheumatol 1994; 21: 462-6
17. Schoen RT, Vender RJ. Mechanism of nonsteroidal anti-inflammatory drug induced gastric damage. Am J Med 1989; 86: 449-57
18. Blanco A, Habib A, Levy-Toledano S, et al. Involvement of tyrosine kinases in the induction of cyclooxygenase-2 in human endothelial cells. Biochem J 1995; 312 (Pt 2): 419-23
19. Inoue H, Yokoyama C, Hara S, et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995; 270 (42): 249675-1
20. Rimarachin JA, Jacobson JA, Szabo P, et al. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14 (7): 1021-31
21. Akai Y, Homma T, Burns KD, et al. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase. Am J Physiol 1994; 267: C482-90
22. Martin M, Neumann D, Hoff T, et al. Interleukin-1 induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994; 45: 150-8
23. Yamagata K, Andreasson KI, Kauffman WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11 (2): 371-86
24. Adams, Cillaco-Morase Y, De Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66 (1): 6-13
25. Vanderburgh HH, Shansky J, Solerssi R, et al. Mechanical stimulation of skeletal muscle increases prostaglandin F2 alpha production, cyclooxygenase activity, and cell growth by a pertussin toxin sensitive mechanism. J Cell Physiol 1995; 163 (2): 285-94
26. Jacobs AL, Hwang D, Julian J, et al. Regulated expression of prostaglandin endoperoxide synthase-2 by uterine stroma. Endocrinology 1994; 135: 1807-15
27. Slater DM, Berger LC, Newton, et al. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynaecol; 172 (1 Pt 1): 77-82
28. Englehardt G. Meloxicam: a potent inhibitor of COX2 [abstract]. 9th International Conference on Prostaglandins and Related Compounds: 1994 Jun 6-10; Florence: 82
29. Meade EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin enderoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268 (9): 6610-4
30. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible COX1. Proc Natl Acad Sci USA 1994; 90: 11163-697
31. Barnett J, Chow J, Ives D, et al. Purification, characterisation and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209 (1): 130-9
32. Langman MJS, Weil J. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
33. Garcia Rodriguez, LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
34. Singh G, Ramey DR, Morfeld D, et al. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994; 62: 175-91
35. Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990; 34: 121-30
36. Richardson CE, Emery P. Innovative treatment approaches for rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9 (4): 731-58
37. Blower PR. The unique pharmacological profile of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 13-9
38. Gerson GC. Worldwide safety experience with nabumetone. J Rheumatol 1992; 19 Suppl. 36: 48-56
39. Wilkens RF. An overview of the long term safety experience of nabumetone. Drugs 1990; 40 Suppl. 5: 34-7
40. Fleishman RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol 1992; 19 Suppl. 36: 32-40
41. Jackson RE, Mitchell FN, Brindley DA. Safety evaluation of nabumetone in US clinical trials. Am J Med 1987; 83 Suppl. 4B: 115-20
42. Jenner PM, Johnson ES. Review of experience with nabumetone in clinical trials outside of the United States. Am J Med 1987; 83 Suppl. 4B: 110-4
43. Inman WHW, Wilton WV, Pearce GI, et al. Prescription event monitoring with nabumetone. Pharm Med 1990; 4: 309-17
44. Hochberg MC. Association of non steroidal anti-inflammatory drugs with upper gastrointestinal disease: epidemiological and economic considerations. J Rheumatol 1992; 19 Suppl. 36: 63-7
45. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322: 909-16
46. Arnoff GR. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 25-31
47. Schattenkirchner M. An updated safely profile of etodolac in several thousand patients. Eur J Rheumalol Inflamm 1990; 10: 56-65
48. Tana AS, McLaughlin S, Holland PJ, et al. Effect on gastric and duodenal mucosal prostaglandins of repeated intake ot therapeutic doses of naproxen and elodolac in rheumatoid arthritis. Ann Rheum Dis 1990; 49: 354-8
49. Lee DKH. Effect of etodolac on the prostaglandin concentration in the kidney of the normal rat. Drug Dev Res 1986; 9 (4): 305-11
50. Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHs-2) versus PGHS1. Eur J Pharmacol 1995; 281: 107-11
51. Turck D, Roth W, Busch U. A review of the pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35 Suppl.: 13-6
52. Degner F, Heinzel G, Busch U. Transsynovial kinetics of meloxicam [abstract]. Scand J Rheumatol 1994; suppl. 98: 121
53. 14C] meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 1990; 16: 49-52
54. Englehart JG, Bogel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism. Part II. In vitro findings. Biochem Pharmacol 1996; 51 (1): 29-38
55. Distel M, Mueller C, Bluhmki E, et al. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35 Suppl. 1; 68-77
56. Linden B, Distel M, Bluhmki E. A double blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 Suppl. 1: 35-8
57. Hosie J, Distel M, Blumhki E. Meloxicam in osteoarthritis: a 6 month double blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35 Suppl. 1: 39-43
58. Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six month double blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl. 1: 22-9
59. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID in daily oral doses of 15, 30 and 60mg in comparison with 20mg piroxicam in patients with rheumatoid arthritis [abstract]. Stand J Rheumatol 1994; Suppl. 98: 115
60. Huskisson EC, Ghozian R, Kurthen R, et al. A long term study to evaluate the safely and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl. 1: 29-34
61. Dinchuck JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking eyclooxygenase II. Nature 1995; 378: 406-9